|
|
|
|
|||||
|
|
|
Purple Achieves Improved Net Loss and Positive Adjusted EBITDA, Advancing Its Profitability Turnaround
Rejuvenate 2.0 Drives Continued Product and Brand Momentum
Mattress Firm Rollout Remains on Track, Supporting Growth in Premium Segment
LEHI, Utah, Nov. 4, 2025 /PRNewswire/ -- Purple Innovation, Inc. (NASDAQ: PRPL) ("Purple"), a comfort innovation company whose mattresses promise to give you "less pain, better sleep," today announced results for the third quarter ended September 30, 2025.
"Our third quarter results reflect the continued progress we're making in strengthening Purple's foundation and positioning the company for sustainable, profitable growth," said Rob DeMartini, CEO of Purple Innovation. "We delivered results in line with expectations, achieving an improved net loss and positive adjusted EBITDA and a sequential improvement in gross margin despite tariff headwinds. These results highlight the discipline and focus that are driving improved performance across our business."
DeMartini continued, "One year after launching our restructuring program, Purple is a leaner, more agile company that is now firmly focused on scaling for growth. The success of Rejuvenate 2.0, the ongoing expansion of our Mattress Firm partnership, and strong showroom performance all underscore the power of our innovation and our brand momentum, marking an important inflection point in sales trends after consecutive quarters of year-over-year declines. We are entering the final months of the year with confidence, executing against our Path to Premium Sleep strategy and remaining on track to deliver positive adjusted EBITDA for the full year."
Third Quarter 2025 Financial Results
Third quarter 2025 net revenue was $118.8 million, up slightly compared to $118.6 million in the third quarter of 2024, fueled by the timing of Rejuvenate 2.0 shipments and the continued expansion of our Mattress Firm partnership. Strength across showroom and wholesale channels was partially offset by softer performance in e-commerce.
Gross profit for the third quarter increased to $50.9 million or 42.8% of net revenue, compared to $35.2 million or 29.7% in the prior year period. Adjusted gross margin, which excludes restructuring and related charges, expanded by 230 basis points to 42.8% in the quarter, compared to 40.5% in the year-prior period. With the restructuring now complete, we also benefited as product continues to scale at our Georgia facility, and we delivered greater manufacturing efficiencies and direct material cost savings.
Third quarter operating expenses were $63.0 million, down 23.2% from $82.0 million in the prior year quarter. The improvement was primarily driven by the comparison to significant restructuring, impairment, and related charges recorded last year, which declined by $13.6 million. Adjusted operating expenses, which excludes certain restructuring and impairment charges, were $57.7 million, down $5.4 million from the prior year period.
Net loss attributable to Purple Innovation, Inc. for the third quarter was $11.7 million, a decline from $39.2 million in the prior year.
Adjusted EBITDA for the third quarter was $0.2 million, an improvement from $(6.4) million last year, driven primarily by our strong gross margin performance and disciplined cost management.
Balance Sheet
As of September 30, 2025, the Company had cash and cash equivalents of $32.4 million compared to $29.0 million as of December 31, 2024.
Net inventories as of September 30, 2025, totaled $65.8 million, up 9.8% compared to September 30, 2024, and an increase of 15.7% compared to December 31, 2024.
2025 Outlook
The Company is maintaining its 2025 guidance, projecting full-year revenue of $465 to $485 million and adjusted EBITDA of breakeven to $10 million, supported by the strong performance of the Rejuvenate 2.0 mattress launch and the successful rollout of the Mattress Firm partnership.
Conference Call and Webcast Information
Purple Innovation, Inc. will host a live conference call to discuss financial results today, November 4, 2025, at 4:30 p.m. Eastern Time. To access the call dial 800-715-9871 (domestic) or 646-307-1963 (international). The call is also being webcast and can be accessed on the investor relations section of the Company's website, investors.purple.com. After the conference call, a webcast replay will remain available on the investor relations section of the Company's website for 30 days.
About Purple
Purple is a premium mattress company and the leader in sleep technology. Their patented GelFlex Grid® is the only material that instantly relieves pressure for less pain and better sleep.
With over 30 years of innovation, Purple's product engineers are paving the way for everyone to experience a proven, deeper sleep by reducing their aches and pains. The GelFlex Grid® does it all—it instantly adapts as you move, balances temperature, relieves pressure, and offers support in all the right places. Purple products, including mattresses, pillows, cushions, frames, sheets, and more, can be found online at Purple.com, in 55 Purple stores, and over 3,800 retailers nationwide.
Purple
Less pain. Better sleep.
Forward Looking Statements
Certain statements made in this release that are not historical facts are "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Statements based on historical data are not intended and should not be understood to indicate the Company's expectations regarding future events. Forward-looking statements provide current expectations or forecasts of future events or determinations. These statements include, but are not limited to, statements regarding our innovation pipeline, the timing of new product collection launches, our ability to improve profitability and optimize our business, the expansion of and benefits to us from our commercial relationship with Mattress Firm, the impact of other commercial relationships, including those with Walmart, Costco, and other traditional and non-traditional partners, revenue-to-date for the third quarter, our ability to drive profitable growth and create shareholder value, and our outlook for revenue and adjusted EBITDA for the full year 2025. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Factors that could influence the realization of forward-looking statements include, among others: changes in economic, financial and end-market conditions in the markets in which we operate; fluctuations in raw material prices and cost of labor; the financial condition of our customers and suppliers; competitive pressures, including the need for technology improvement, successful new product development and introduction; changes in consumer demand, including pullbacks in consumer spending; disruptions to our manufacturing processes; and the risk factors outlined in the "Risk Factors" section of our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 14, 2025, and in our other filings made with the SEC. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Non-GAAP Financial Measures
EBITDA, adjusted operating expenses, adjusted EBITDA, adjusted gross margin, adjusted net income, and adjusted net income per diluted share are non-GAAP financial measures that remove the impact of certain non-cash and non-recurring costs. Management believes that the use of such non-GAAP financial measures provides investors with additional useful information with respect to the impact of various adjustments, which we view as a better measure of our operating performance. Refer to the attached table for the reconciliation of such non-GAAP financial measures to the most comparable GAAP financial measure.
With respect to the Company's Adjusted EBITDA outlook for the full year 2025, a quantitative reconciliation to the corresponding GAAP information cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted, including but not limited to warrant liabilities and stock based compensation. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.
Investor Contact:
Stacy Turnof, Edelman Smithfield
[email protected]
917-362-2581
|
PURPLE INNOVATION, INC. Condensed Consolidated Balance Sheets (unaudited – in thousands, except for par value) |
|||||||
|
|
|||||||
|
|
|
September 30, |
|
|
December 31, |
||
|
2025 |
2024 |
||||||
|
Assets |
|
|
|
|
|
||
|
Current assets: |
|
|
|
|
|
||
|
Cash and cash equivalents |
|
$ |
32,358 |
|
|
$ |
29,011 |
|
Accounts receivable, net |
|
|
25,210 |
|
|
|
33,057 |
|
Inventories |
|
|
65,770 |
|
|
|
56,863 |
|
Prepaid expenses |
|
|
7,401 |
|
|
|
6,023 |
|
Other current assets |
|
|
5,667 |
|
|
|
1,414 |
|
Total current assets |
|
|
136,406 |
|
|
|
126,368 |
|
Property and equipment, net |
|
|
79,495 |
|
|
|
93,874 |
|
Operating lease right-of-use assets |
|
|
70,668 |
|
|
|
75,516 |
|
Intangible assets, net |
|
|
6,895 |
|
|
|
8,890 |
|
Other long-term assets |
|
|
8,657 |
|
|
|
3,197 |
|
Total assets |
|
$ |
302,121 |
|
|
$ |
307,845 |
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
35,661 |
|
|
$ |
40,639 |
|
Accrued compensation |
|
|
7,765 |
|
|
|
9,415 |
|
Customer prepayments |
|
|
5,209 |
|
|
|
6,411 |
|
Accrued rebates and allowances |
|
|
13,820 |
|
|
|
10,013 |
|
Accrued warranty liabilities – current portion |
|
|
7,635 |
|
|
|
6,114 |
|
Operating lease obligations – current portion |
|
|
16,379 |
|
|
|
15,661 |
|
Other current liabilities |
|
|
10,628 |
|
|
|
12,750 |
|
Total current liabilities |
|
|
97,097 |
|
|
|
101,003 |
|
Related party debt |
|
|
102,889 |
|
|
|
55,394 |
|
Accrued warranty liabilities, net of current portion |
|
|
24,163 |
|
|
|
26,091 |
|
Operating lease obligations, net of current portion |
|
|
80,837 |
|
|
|
87,072 |
|
Warrant liabilities |
|
|
22,032 |
|
|
|
16,067 |
|
Other long-term liabilities |
|
|
2,010 |
|
|
|
2,009 |
|
Total liabilities |
|
|
329,028 |
|
|
|
287,636 |
|
Commitments and contingencies (Note 13) |
|
|
|
|
|
|
|
|
Stockholders' equity (deficit): |
|
|
|
|
|
|
|
|
Class A common stock; $0.0001 par value, 210,000 shares authorized; 108,246 issued and outstanding at September 30, |
|
|
11 |
|
|
|
11 |
|
Class B common stock; $0.0001 par value, 90,000 shares authorized; 163 issued and outstanding at September 30, 2025, |
|
|
— |
|
|
|
— |
|
Additional paid-in capital |
|
|
595,118 |
|
|
|
594,053 |
|
Accumulated deficit |
|
|
(622,068) |
|
|
|
(573,866 |
|
Total stockholders' equity (deficit) attributable to Purple Innovation, Inc. |
|
|
(26,939) |
|
|
|
20,198 |
|
Noncontrolling interest |
|
|
32 |
|
|
|
11 |
|
Total stockholders' equity (deficit) |
|
|
(26,907) |
|
|
|
20,209 |
|
Total liabilities and stockholders' equity (deficit) |
|
$ |
302,121 |
|
|
$ |
307,845 |
|
PURPLE INNOVATION, INC. Condensed Consolidated Statements of Operations (unaudited – in thousands, except per share amounts) |
|
|||||||||||||||
|
|
|
|||||||||||||||
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
September 30, |
September 30, |
|||||||||||||||
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
|
Revenues, net |
|
$ |
118,766 |
|
|
$ |
118,598 |
|
|
$ |
328,037 |
|
|
$ |
358,902 |
|
|
Cost of revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues |
|
|
67,915 |
|
|
|
70,546 |
|
|
|
197,462 |
|
|
|
220,190 |
|
|
Cost of revenues - restructuring related charges |
|
|
— |
|
|
|
12,859 |
|
|
|
995 |
|
|
|
12,859 |
|
|
Total cost of revenues |
|
|
67,915 |
|
|
|
83,405 |
|
|
|
198,457 |
|
|
|
233,049 |
|
|
Gross profit |
|
|
50,851 |
|
|
|
35,193 |
|
|
|
129,580 |
|
|
|
125,853 |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Marketing and sales |
|
|
40,120 |
|
|
|
42,939 |
|
|
|
107,362 |
|
|
|
125,778 |
|
|
General and administrative |
|
|
15,200 |
|
|
|
17,266 |
|
|
|
44,678 |
|
|
|
55,111 |
|
|
Research and development |
|
|
2,367 |
|
|
|
2,920 |
|
|
|
6,997 |
|
|
|
10,572 |
|
|
Restructuring, impairment and other related charges |
|
|
5,290 |
|
|
|
18,881 |
|
|
|
11,387 |
|
|
|
18,881 |
|
|
Total operating expenses |
|
|
62,977 |
|
|
|
82,006 |
|
|
|
170,424 |
|
|
|
210,342 |
|
|
Operating loss |
|
|
(12,126) |
|
|
|
(46,813) |
|
|
|
(40,844) |
|
|
|
(84,489) |
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
(8,203) |
|
|
|
(4,394) |
|
|
|
(20,424) |
|
|
|
(13,029) |
|
|
Other income, net |
|
|
1,742 |
|
|
|
7,165 |
|
|
|
1,812 |
|
|
|
11,612 |
|
|
Loss on extinguishment of debt |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(3,394) |
|
|
Change in fair value – warrant liabilities |
|
|
6,892 |
|
|
|
4,795 |
|
|
|
11,319 |
|
|
|
(111) |
|
|
Total other income (expense), net |
|
|
431 |
|
|
|
7,566 |
|
|
|
(7,293) |
|
|
|
(4,922) |
|
|
Net loss before income taxes |
|
|
(11,695) |
|
|
|
(39,247) |
|
|
|
(48,137) |
|
|
|
(89,411) |
|
|
Income tax expense |
|
|
(53) |
|
|
|
(63) |
|
|
|
(148) |
|
|
|
(176) |
|
|
Net loss |
|
|
(11,748) |
|
|
|
(39,310) |
|
|
|
(48,285) |
|
|
|
(89,587) |
|
|
Net loss attributable to noncontrolling interest |
|
|
(28) |
|
|
|
(82) |
|
|
|
(83) |
|
|
|
(169) |
|
|
Net loss attributable to Purple Innovation, Inc. |
|
$ |
(11,720) |
|
|
$ |
(39,228) |
|
|
$ |
(48,202) |
|
|
$ |
(89,418) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
(0.11) |
|
|
$ |
(0.36) |
|
|
$ |
(0.45) |
|
|
$ |
(0.84) |
|
|
Diluted |
|
$ |
(0.11) |
|
|
$ |
(0.36) |
|
|
$ |
(0.45) |
|
|
$ |
(0.84) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
108,245 |
|
|
|
107,508 |
|
|
|
108,026 |
|
|
|
107,008 |
|
|
Diluted |
|
|
108,409 |
|
|
|
107,508 |
|
|
|
108,191 |
|
|
|
107,008 |
|
|
PURPLE INNOVATION, INC. Condensed Consolidated Statements of Cash Flows (unaudited – in thousands) |
|
|||||||
|
|
|
|||||||
|
|
|
Nine Months Ended |
|
|||||
|
|
|
2025 |
|
|
2024 |
|
||
|
Cash flows from operating activities: |
|
|
|
|
|
|
||
|
Net loss |
|
$ |
(48,285) |
|
|
$ |
(89,587) |
|
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
19,659 |
|
|
|
27,448 |
|
|
Non-cash interest |
|
|
9,537 |
|
|
|
5,303 |
|
|
Paid-in-kind interest |
|
|
11,266 |
|
|
|
7,028 |
|
|
Non-cash restructuring, impairment and other related charges |
|
|
3,775 |
|
|
|
20,115 |
|
|
Loss on extinguishment of debt |
|
|
— |
|
|
|
3,394 |
|
|
Loss on disposal of property and equipment |
|
|
318 |
|
|
|
770 |
|
|
Change in fair value – warrant liabilities |
|
|
(11,319) |
|
|
|
111 |
|
|
Stock-based compensation |
|
|
1,265 |
|
|
|
2,108 |
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
7,847 |
|
|
|
8,140 |
|
|
Inventories |
|
|
(8,907) |
|
|
|
2,971 |
|
|
Prepaid expenses and other assets |
|
|
755 |
|
|
|
378 |
|
|
Operating leases, net |
|
|
(2,080) |
|
|
|
(2,105) |
|
|
Accounts payable |
|
|
(4,464) |
|
|
|
(16,558) |
|
|
Accrued compensation |
|
|
(1,650) |
|
|
|
10,045 |
|
|
Customer prepayments |
|
|
(1,202) |
|
|
|
(1,940) |
|
|
Accrued rebates and allowances |
|
|
307 |
|
|
|
(3,203) |
|
|
Accrued warranty liabilities |
|
|
(407) |
|
|
|
(621) |
|
|
Other accrued liabilities |
|
|
(4,445) |
|
|
|
1,592 |
|
|
Net cash used in operating activities |
|
|
(28,030) |
|
|
|
(24,611) |
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
|
Sale of property and equipment |
|
|
464 |
|
|
|
— |
|
|
Purchase of property and equipment |
|
|
(6,076) |
|
|
|
(6,160) |
|
|
Investment in intangible assets |
|
|
(454) |
|
|
|
(221) |
|
|
Net cash used in investing activities |
|
|
(6,066) |
|
|
|
(6,381) |
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|
Proceeds from related party loan |
|
|
39,000 |
|
|
|
61,000 |
|
|
Payments on term loan |
|
|
— |
|
|
|
(25,000) |
|
|
Payments on revolving line of credit |
|
|
— |
|
|
|
(5,000) |
|
|
Payments for debt issuance costs |
|
|
(1,557) |
|
|
|
(3,466) |
|
|
Net cash provided by financing activities |
|
|
37,443 |
|
|
|
27,534 |
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents |
|
|
3,347 |
|
|
|
(3,458) |
|
|
Cash and cash equivalents, beginning of the year |
|
|
29,011 |
|
|
|
26,857 |
|
|
Cash and cash equivalents, end of the period |
|
$ |
32,358 |
|
|
$ |
23,399 |
|
PURPLE INNOVATION, INC.
RECONCILIATION OF GAAP TO NON-GAAP MEASURES
(In thousands)
Management believes that the use of the following non-GAAP financial measures provides investors with additional useful information with respect to the impact of various adjustments, which we view as a better measure of our operating performance. These non-GAAP financial measures are EBITDA, adjusted EBITDA, adjusted operating expenses, adjusted net loss and adjusted net loss per diluted share. Other companies may calculate these non-GAAP measures differently than we do. These non-GAAP measures have limitations as analytical tools, and you should not consider them in isolation or as a substitute for our financial results prepared in accordance with GAAP.
Reconciliation of GAAP Net Income (Loss) to Non-GAAP EBITDA and Adjusted EBITDA
A reconciliation of GAAP net income (loss) to the non-GAAP measures of EBITDA and adjusted EBITDA is provided below. EBITDA represents net income (loss) before interest expense, income tax expense, other income, net, and depreciation and amortization. Adjusted EBITDA represents EBITDA excluding costs incurred due to changes in the fair value of the warrant liability, debt extinguishment, stock-based compensation expense, restructuring related expenses, loss on project write-off, nonrecurring and debt issuance legal fees, Board special committee costs, executive interim and search costs, severance cost, showroom opening and closing costs and non-operating facility expense. We believe EBITDA and Adjusted EBITDA provide additional useful information with respect to the impact of various adjustments and provide meaningful measures of our operating performance.
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
GAAP net loss |
|
$ |
(11,748) |
|
|
|
(39,310) |
|
|
|
(48,285) |
|
|
|
(89,587) |
|
|
Interest expense |
|
|
8,203 |
|
|
|
4,394 |
|
|
|
20,424 |
|
|
|
13,029 |
|
|
Income tax expense |
|
|
53 |
|
|
|
63 |
|
|
|
148 |
|
|
|
176 |
|
|
Other income, net |
|
|
(1,742) |
|
|
|
(7,165) |
|
|
|
(1,812) |
|
|
|
(11,612) |
|
|
Depreciation and amortization |
|
|
9,777 |
|
|
|
14,627 |
|
|
|
19,658 |
|
|
|
27,448 |
|
|
EBITDA |
|
|
4,543 |
|
|
|
(27,391) |
|
|
|
(9,867) |
|
|
|
(60,546) |
|
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in fair value - warrant liability |
|
|
(6,893) |
|
|
|
(4,795) |
|
|
|
(11,320) |
|
|
|
111 |
|
|
Loss on extinguishment of debt |
|
|
— |
|
|
|
— |
|
|
|
795 |
|
|
|
3,394 |
|
|
Stock-based compensation expense |
|
|
420 |
|
|
|
791 |
|
|
|
1,265 |
|
|
|
2,108 |
|
|
Restructuring related charges |
|
|
65 |
|
|
|
23,669 |
|
|
|
6,850 |
|
|
|
23,669 |
|
|
Loss on project write-off |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,355 |
|
|
Non-recurring and debt issuance legal fees |
|
|
310 |
|
|
|
16 |
|
|
|
655 |
|
|
|
940 |
|
|
Strategic alternative costs |
|
|
698 |
|
|
|
— |
|
|
|
1,958 |
|
|
|
— |
|
|
Executive interim and search costs |
|
|
— |
|
|
|
409 |
|
|
|
— |
|
|
|
3,383 |
|
|
Severance costs |
|
|
82 |
|
|
|
202 |
|
|
|
1,652 |
|
|
|
1,086 |
|
|
Showroom opening and closing costs |
|
|
— |
|
|
|
724 |
|
|
|
147 |
|
|
|
782 |
|
|
Non-operating facility expense |
|
|
964 |
|
|
|
— |
|
|
|
964 |
|
|
|
— |
|
|
Adjusted EBITDA |
|
$ |
189 |
|
|
$ |
(6,375) |
|
|
$ |
(6,901) |
|
|
$ |
(23,718) |
|
Reconciliation of GAAP Gross Profit to Adjusted Gross Profit
A reconciliation of GAAP gross profit to the non-GAAP measures of adjusted gross profit is provided below. Adjusted gross profit represents net revenue less adjusted cost of revenues. Adjusted cost of revenues represents cost of revenues excluding restructuring charges recorded in cost of revenues. We believe adjusted gross margin provides additional useful information with respect to the impact of the restructuring and provides meaningful measures of our operating performance.
|
(in thousands) |
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
|
Revenues, net |
|
$ |
118,766 |
|
|
$ |
118,598 |
|
|
$ |
328,037 |
|
|
$ |
358,902 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total cost of revenues |
|
|
67,915 |
|
|
|
83,405 |
|
|
|
198,457 |
|
|
|
233,049 |
|
|
Restructuring charges in cost of revenues |
|
|
— |
|
|
|
(12,859) |
|
|
|
(995) |
|
|
|
(12,859) |
|
|
Adjusted cost of revenues |
|
|
67,915 |
|
|
|
70,546 |
|
|
|
197,462 |
|
|
|
220,190 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted gross profit |
|
$ |
50,851 |
|
|
$ |
48,052 |
|
|
$ |
130,575 |
|
|
$ |
138,712 |
|
|
Adjusted gross profit % |
|
|
42.8 % |
|
|
|
40.5 % |
|
|
|
39.8 % |
|
|
|
38.6 % |
|
Reconciliation of GAAP Operating Expenses to non-GAAP Adjusted Operating Expenses
Our presentation of adjusted operating expenses assumes adjustments for certain nonrecurring items that we do not believe directly reflects our current core operations. Adjusted operating expenses is a supplemental measure of operating performance that does not represent, and should not be considered, alternatives to net loss and earnings per share, as calculated in accordance with GAAP. We believe adjusted operating expenses supplements GAAP measures and enables us to more effectively evaluate our performance period-over-period. A reconciliation of operating expenses, the most directly comparable GAAP measure, to adjusted operating expenses is set forth below:
|
(in thousands, except per share amounts) |
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
|
Total operating expenses |
|
$ |
62,977 |
|
|
$ |
82,006 |
|
|
$ |
170,424 |
|
|
$ |
210,342 |
|
|
Restructuring, impairment and other related charges |
|
|
(5,290) |
|
|
|
(18,881) |
|
|
|
(11,387) |
|
|
|
(18,881) |
|
|
Adjusted operating expenses |
|
$ |
57,687 |
|
|
$ |
63,125 |
|
|
$ |
159,037 |
|
|
$ |
191,461 |
|
Reconciliation of GAAP Net Loss to non-GAAP Adjusted Net Loss and Adjusted Net Loss per Diluted Share
Our presentation of adjusted net loss assumes that all net loss is attributable to Purple Innovation, Inc. (i.e. there is no allocation of net loss to noncontrolling interests), which assumes the full exchange at the beginning of the period of all outstanding Paired Securities for shares of Class A common stock of Purple Innovation, Inc., adjusted for certain nonrecurring items that we do not believe directly reflect our core operations. Adjusted net loss per share, diluted, is calculated by dividing adjusted net loss by the total shares of Class A common stock outstanding plus any dilutive warrants, options and restricted stock as calculated in accordance with GAAP and assuming the full exchange of all outstanding Paired Securities as of the beginning of each period presented. Adjusted net loss and adjusted net loss per diluted share, are supplemental measures of operating performance that do not represent, and should not be considered, alternatives to net loss and earnings per share, as calculated in accordance with GAAP. We believe adjusted net loss and adjusted net loss per diluted share, supplement GAAP measures and enable us to more effectively evaluate our performance period-over-period. A reconciliation of net loss, the most directly comparable GAAP measure, to adjusted net loss and the computation of adjusted net loss per diluted share, are set forth below:
|
(in thousands, except per share amounts) |
|
Three Months |
|
|
Nine Months |
|
||||||||||
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
|
Net loss |
|
$ |
(11,748) |
|
|
$ |
(39,310) |
|
|
$ |
(48,285) |
|
|
$ |
(89,587) |
|
|
Income tax (benefit) expense, as reported |
|
|
53 |
|
|
|
63 |
|
|
|
148 |
|
|
|
176 |
|
|
Revenue reduction due to SGI Contract |
|
|
941 |
|
|
|
— |
|
|
|
1,568 |
|
|
|
— |
|
|
Change in fair value – warrant liabilities |
|
|
(6,892) |
|
|
|
(4,795) |
|
|
|
(11,319) |
|
|
|
111 |
|
|
Loss on extinguishment of debt |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
3,394 |
|
|
Restructuring related charges |
|
|
5,290 |
|
|
|
32,682 |
|
|
|
12,382 |
|
|
|
32,682 |
|
|
Gain on insurance proceeds |
|
|
— |
|
|
|
(7,301) |
|
|
|
— |
|
|
|
(11,601) |
|
|
Board special committee fees |
|
|
698 |
|
|
|
— |
|
|
|
1,958 |
|
|
|
— |
|
|
Adjusted net loss before income taxes |
|
|
(11,658) |
|
|
|
(18,661) |
|
|
|
(43,548) |
|
|
|
(64,825) |
|
|
Adjusted income tax benefit(1) |
|
|
3,026 |
|
|
|
4,833 |
|
|
|
11,279 |
|
|
|
16,790 |
|
|
Adjusted net loss |
|
$ |
(8,632) |
|
|
$ |
(13,828) |
|
|
$ |
(32,269) |
|
|
$ |
(48,035) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted net loss per share, diluted |
|
$ |
(0.08) |
|
|
$ |
(0.13) |
|
|
$ |
(0.30) |
|
|
$ |
(0.45) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted weighted-average shares outstanding, diluted(2) |
|
|
108,409 |
|
|
|
107,703 |
|
|
|
108,191 |
|
|
|
107,203 |
|
|
|
|
(1) Represents the estimated effective tax rate of 25.9% for the three and nine months ended September 30, 2025 and 2024, applied to adjusted net income before income taxes. The estimated effective tax rates are what the Company would be subject to and consist of the combined federal statutory tax rate and the Company's blended state tax rates. |
|
|
|
(2) Assumes options and restricted stock units calculated in accordance with GAAP and the full exchange of all outstanding Paired Securities for shares of Class A common stock as of the beginning of the period. |
A reconciliation of net income (loss) per share, diluted, to adjusted net loss per diluted share is set forth below for the three and nine months ended September 30, 2025 and 2024:
|
|
|
For the Three Months Ended |
|
|||||||||||||||||||||
|
|
|
September 30, 2025 |
|
|
September 30, 2024 |
|
||||||||||||||||||
|
|
|
Net Loss |
|
|
Weighted |
|
|
Net Income |
|
|
Net Loss |
|
|
Weighted |
|
|
Net Income |
|
||||||
|
Net loss attributable to Purple Innovation Inc.(1) |
|
$ |
(11,720) |
|
|
|
108,409 |
|
|
|
(0.11) |
|
|
$ |
(39,228) |
|
|
|
107,508 |
|
|
$ |
(0.36) |
|
|
Assumed exchange of shares(2) |
|
|
(28) |
|
|
|
— |
|
|
|
|
|
|
|
(82) |
|
|
|
195 |
|
|
|
|
|
|
Net loss |
|
|
(11,748) |
|
|
|
|
|
|
|
|
|
|
|
(39,310) |
|
|
|
|
|
|
|
|
|
|
Adjustments to arrive at adjusted loss before taxes(3) |
|
|
90 |
|
|
|
|
|
|
|
|
|
|
|
20,649 |
|
|
|
|
|
|
|
|
|
|
Adjusted loss before taxes |
|
|
(11,658) |
|
|
|
|
|
|
|
|
|
|
|
(18,661) |
|
|
|
|
|
|
|
|
|
|
Adjusted income tax benefit(4) |
|
|
3,026 |
|
|
|
|
|
|
|
|
|
|
|
4,833 |
|
|
|
|
|
|
|
|
|
|
Adjusted net loss |
|
$ |
(8,632) |
|
|
|
108,409 |
|
|
|
(0.08) |
|
|
$ |
(13,828) |
|
|
|
107,703 |
|
|
$ |
(0.13) |
|
|
|
|
(1) Represents net loss attributable to Purple Innovation, Inc. and the associated weighted average diluted shares, of Class A common stock outstanding. For the three months ended September 30, 2025, the Paired Securities are included in the beginning weighted average shares, diluted. |
|
|
|
(2) Assumes the full exchange of all outstanding Paired Securities for shares of Class A common stock as of the beginning of the period if not already included in weighted average diluted shares in footnote (1) above. Also assumes the addition of net income attributable to noncontrolling interests corresponding with the assumed exchange of the Paired Securities for shares of Class A common stock. |
|
|
|
(3) Represents the total impact of all adjustments identified in the adjusted net income table above to arrive at adjusted income before income taxes. Also assumes the dilutive warrants, options and restricted stock as calculated in accordance with GAAP. |
|
|
|
(4) Represents the estimated effective tax rate of 25.9% for the three months ended September 30, 2025 and 2024, applied to adjusted net income before income taxes. The estimated effective tax rates are what the Company would be subject to and consist of the combined federal statutory tax rate and the Company's blended state tax rates assuming no valuation allowance. |
|
|
|
For the Nine Months Ended |
|
|||||||||||||||||||||
|
|
|
September 30, 2025 |
|
|
September 30, 2024 |
|
||||||||||||||||||
|
|
|
Net Income |
|
|
Weighted |
|
|
Net Income |
|
|
Net Income |
|
|
Weighted |
|
|
Net Income |
|
||||||
|
Net loss attributable to Purple Innovation Inc.(1) |
|
$ |
(48,202) |
|
|
|
108,191 |
|
|
|
(0.45) |
|
|
$ |
(89,418) |
|
|
|
107,008 |
|
|
$ |
(0.84) |
|
|
Assumed exchange of shares(2) |
|
|
(83) |
|
|
|
— |
|
|
|
|
|
|
|
(169) |
|
|
|
195 |
|
|
|
|
|
|
Net loss |
|
|
(48,285) |
|
|
|
|
|
|
|
|
|
|
|
(89,587) |
|
|
|
|
|
|
|
|
|
|
Adjustments to arrive at adjusted loss before taxes(3) |
|
|
4,737 |
|
|
|
|
|
|
|
|
|
|
|
24,762 |
|
|
|
|
|
|
|
|
|
|
Adjusted loss before taxes |
|
|
(43,548) |
|
|
|
|
|
|
|
|
|
|
|
(64,825) |
|
|
|
|
|
|
|
|
|
|
Adjusted income tax benefit(4) |
|
|
11,279 |
|
|
|
|
|
|
|
|
|
|
|
16,790 |
|
|
|
|
|
|
|
|
|
|
Adjusted net loss |
|
$ |
(32,269) |
|
|
|
108,191 |
|
|
|
(0.30) |
|
|
$ |
(48,035) |
|
|
|
107,203 |
|
|
$ |
(0.45) |
|
|
|
|
(1) Represents net loss attributable to Purple Innovation, Inc. and the associated weighted average diluted shares, of Class A common stock outstanding. For the nine months ended September 30, 2025, the Paired Securities are included in the beginning weighted average shares, diluted. |
|
|
|
(2) Assumes the full exchange of all outstanding Paired Securities for shares of Class A common stock as of the beginning of the period if not already included in weighted average diluted shares in footnote (1) above. Also assumes the addition of net income attributable to noncontrolling interests corresponding with the assumed exchange of the Paired Securities for shares of Class A common stock. |
|
|
|
(3) Represents the total impact of all adjustments identified in the adjusted net income table above to arrive at adjusted income before income taxes. Also assumes the dilutive warrants, options and restricted stock as calculated in accordance with GAAP. |
|
|
|
(4) Represents the estimated effective tax rate of 25.9% for the nine months ended September 30, 2025 and 2024, applied to adjusted net income before income taxes. The estimated effective tax rates are what the Company would be subject to and consist of the combined federal statutory tax rate and the Company's blended state tax rates assuming no valuation allowance. |
SOURCE Purple Innovation, LLC
| 7 hours | |
| 16 hours | |
| Nov-04 | |
| Nov-04 | |
| Nov-04 | |
| Nov-04 | |
| Nov-03 | |
| Nov-02 | |
| Oct-31 | |
| Oct-29 | |
| Oct-07 | |
| Sep-02 | |
| Aug-31 | |
| Aug-21 | |
| Aug-12 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite